Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Main objective of the trial
To determine the effect of AZD1656 on the cardiorespiratory complications of COVID-19 in hospitalised diabetic patients with known or suspected COVID-19 disease, (ie inflammation of the heart muscle, pericarditis is inflammation of the lining outside the heart. In both cases, the body's immune system is causing inflammation in response to an infection)
AZD1656 (AZD1656 (GCK activator, 1 µM) has been shown to activate the migration of T regulatory cells to sites of inflammation in preclinical experiments. This migration of Treg cells to inflamed tissue is crucial for their immune-modulatory function (Kishore et al (2017) GCK activation significantly enhanced Treg cell migration to the inflamed tissue. Tregs not only maintain the tone and tenor of an immune response by dominant tolerance but have also been identified as key players in resolving tissue inflammation and as mediators of tissue healing
Research docs link;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714502/
Secondary objectives of the study
To assess the extent to which AZD1656 supports maintenance of adequate glycaemic control in hospitalised diabetic patients with known or suspected COVID-19. ie Glycemic control is a medical term referring to the typical levels of blood sugar (glucose) in a person with diabetes.
AZD 1656 has been found to be safe in almost 1,000 patients with diabetes and has a blood glucose lowering effect for four months ie IMO sufficient to cover the critical period likely in hospital with covid 19. Blood glucose control has been proposed as a key factor in reducing complications from COVID-19 in diabetics. Research docs link;
https://europepmc.org/article/med/22943931
To assess the safety and tolerability of AZD1656 in the management of diabetes in hospitalised diabetic patients with known or suspected COVID-19. AZD1656 has been studied in single doses of up to 180 mg and multiple doses to 150 mg BID for 8 days in healthy volunteers as well as alone and in combination with other blood glucose control agents in diabetic patients at 200 mg daily for up to 6 months duration. In both healthy volunteers and diabetic patients no significant clinical effects other than glucose lowering were noted. Research docs link;
https://openinnovation.astrazeneca.com/azd1656.html
To determine whether AZD1656 affects duration of hospital stay, requirement for mechanical ventilation or mortality in diabetic patients with known or suspected COVID-19.
To be determined in trial.
SGS has acquired the right to develop and commercialise two assets from a major global pharmaceutical company. Link to multiple (24) trials by AstraZenaca on AZD1656;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/SearchResults
I will be increasing my share numbers in the morning but DYOR!
I'm already at my limit positioned myself a few weeks back at just shy of 0.08 , would love to add more at these levels though anything below at 0.1 before news is a bargain
Johnski
I will do my own research but well said sir
I do like this board, proper people
Ouz
The RNS below from Angelfish investments, listed on Aquis, makes for very interesting reading for Vela shareholders. Is this a signal that the ARCADIA trial is proving positive with just 2 weeks to go to the end of the trial?
https://www.aquis.eu/aquis-stock-exchange/member?securityidaqse=ANGP
No one seems to have picked this news up?
In short, Angelfish Investments announced on Friday a major reorganisation, including raising £2m and bringing Professor Sir Christopher Evans on to the Board together with other Excalibur Healthcare Services Directors and founders.
Excalibur has exclusive rights to and owns the patents on a drug, AZD1656, which is being developed as a potential therapeutic for diabetics suffering from COVID-19.
Professor Sir Christopher Evans structured the ARCADIA research project from which St George’s Capital is hoping to be able to commercialise.
The announcement also goes into great detail about AZD1656 and the ARCADIA trial.
So, the question is, why would Professor Sir Christopher Evans be doing such a transaction at this time, right at the end of the trial, if he did not hold out very high expectations that the trial results would be positive?
That is an interesting spot. Well done Jimmy.
Great find and share Jimmy! Worth another top up
Great find Jimmy, I see that Peterhouse Capital is involved which seems to be Vela's go to broker.
Need to read it a few times , slowly, to understand what it all means.
As at date of publication, 156 patients have been recruited and have completed treatment. The data is now being assessed and outcomes will be reported formally on or about late July 2021. It is the intention of EML to seek a sale of the drug, a license or partnership deal as soon as possible after the data is published.
The above is from the Angelfish RNS. Late July for final results, which should mean initial indications are ahead of the "end of June" expectation.
Awesome find Jimmy
Major move around ready to all be rewarded when the positive results come out.
Makes it easy to distribute shares and all be in place if drug gets commercialized
As many have said Jimmy, what a great find you've had! Probably deserves it's own thread
I couldn't open the RNS from the Aquis website so found it on Angelfish's website if anybody needs the link
https://angelfishplc.com/wp-content/uploads/2021/06/Notice-of-GM-Board-Changes-and-Change-of-Adviser.pdf
If this isn't bullish news then i don't know what is :D
GLA
.0827 to sell and it started at .0810 this morning, happy to watch this bubble away till we have news
Credit goes to edcrane on advfn copy and pasted ,
Gla
jimmy it all helps though, and i dont use ADVFN so i wouldnt have seen that post, so thanks x
I think with the new covid delays and cases on increase if arcadia is positive i think will be on national news as be a great story for the fight against covid.
Good luck all great price to get in at !!!
Yes, it certainly looks like it’s all coming together nicely.
GLA
The delay is working out sell for Covid stocks like SNG/VELA. Any news will be covered by all the main news! We have great partners so for VELA we are moving into transformational period for the stock!
Bought 3 million more today!
GLA!
Y-Alam how are you keeping Hun x
All good.... Good to see you here.....
glad your good hun....I only got in last week...
Likewise.... I also got in last week
looks like we both got in at the right time :-)x
The key here is whether Vela is part of the £2m fundraise which certainly looks like a very strong possibility. Should have more info from General Meeting on June 28.
This deal seems to be more about the participation in all future co-investment opportunities with Excalibur. Angelfish invests in EML for cash in return for 2% plus share consideration only if AZD1656 is successful. The current agreement re 8% of proceeds to SGS (less defined costs) should remain intact.
I don't see reference to initial results, will we just have a final report published?
Anyway, next 2 weeks should be quite exciting as we ponder what this all means.
Simon Grant-Rennick:-
Executive Chairman of Angelfish
Independent Non-Executive Director of AAA Capital
:-)
Is Angelfish the mystery 10th investment?
On 23/02 Placing RNS states 9 investments and includes reference to hydrogen investment but did not name Aeristech til 25/02. Subsequently invested in MTI (25/03) and disposed of North Peak (09/04) which should mean the 9 investments in total was retained however this last RNS mentions 10 investments. So between 23/02 and 09/04, a further, as yet unnamed investment was made.
On the 26/04, Angelfish announced a placing of £42k plus a CLF of £90k without mentioning investors by name. This is also when Simon Grant-Rennick was appointed to the Board. If these funds were raised prior to 09/04 but info released a couple of weeks later only once all paperwork was finalised, then feasible that Vela were one of the placing investors & may explain the radio silence.
Thoughts?